leisure time -WSS

leisure time

author：leisure time 2025-08-26 23:44:35 - browse：1

Eric Lander White House science office — Eric Lander resigned as President Biden’s science adviser, after a White House investigation found “credible evidence” that he had violated workplace conduct rules. Photo illustration: Alex Hogan/STAT; Source: Getty

WASHINGTON — An early sign that trouble was afoot in the White House science office came last November, when roughly a dozen of Eric Lander’s staff formed a “culture committee” aimed at improving morale.

The group’s first action, five aides told STAT, was to create a “word cloud” depicting the adjectives they most often used to describe the work environment at the White House Office of Science and Technology Policy. Of the dozens of words submitted, three in particular stood out: “hostile,” “siloed,” and “aggressive.”

Three months later, Lander resigned as President Biden’s science adviser, after Politico reported a White House investigation that found “credible evidence” that he had violated workplace conduct rules.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

WSS

New clues to why women have higher risk of autoimmune disorders

How generative AI ratchets up security threats for health systems

KalVista pill reduced swelling 'attacks' caused by genetic disease

Medicare Advantage insurers face 0.2% cut to 2025 payments

The dental labor crisis is a moment of opportunity

Why Medicare shouldn’t cover every FDA

explore

leisure time

leisure time

Sports medicine is finally prioritizing gender equality

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Tori Bowie and the unacceptable rates of Black maternal death

Medicare threatens to cut off funding for HCA's Mission hospital

As demand for Covid shots wanes, Moderna seeks its next success

Investment in vaccine development is lagging, report finds

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Pancreatic cancer early detection could be helped by AI

How one medical school became remarkably diverse

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

focus

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Medicare drug price negotiation legal challenge met with skepticism

Readout LOUD podcast: How biotech is using artificial intelligence

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Health Care Service Corp to buy Cigna Medicare Advantage plans

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

focus

knowledge

leisure time

explore